Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet's disease.
about
Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapiesMucocutaneous Involvement in Behçet's Disease: How Systemic Treatment Has Changed in the Last Decades and Future PerspectivesBiological treatments in Behçet's disease: beyond anti-TNF therapy.Gain-of-function Pyrin mutations induce NLRP3 protein-independent interleukin-1β activation and severe autoinflammation in mice.Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectivesAn expanding role for interleukin-1 blockade from gout to cancer.Association between MEFV Mutations M694V and M680I and Behçet's Disease: A Meta-AnalysisTreating inflammation by blocking interleukin-1 in a broad spectrum of diseases.Biological treatments: new weapons in the management of monogenic autoinflammatory disordersUpdate on the Medical Management of Gastrointestinal Behçet's Disease.Treating inflammation by blocking interleukin-1 in humans.The effect of anakinra on retinal function in isolated perfused vertebrate retina.The emerging role of interleukin-1β in autoinflammatory diseases.The Eurofever Project: towards better care for autoinflammatory diseases.Renal amyloidosis in children.The NLRP3 inflammasome in health and disease: the good, the bad and the ugly.Immunology in clinic review series; focus on autoinflammatory diseases: update on monogenic autoinflammatory diseases: the role of interleukin (IL)-1 and an emerging role for cytokines beyond IL-1.Type I IFN-mediated regulation of IL-1 production in inflammatory disorders.IL-1β biological treatment of familial Mediterranean fever.Refractory pemphigus foliaceus and Behçet's disease successfully treated with tocilizumab.Novel therapeutics for the treatment of familial Mediterranean fever: from colchicine to biologics.Familial mediterranean fever: a fascinating model of inherited autoinflammatory disorder.Biologic therapy in familial Mediterranean fever.New therapeutic solutions for Behçet's syndrome.Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet's disease-related uveitis: a multicenter retrospective observational study.The experience of canakinumab in renal amyloidosis secondary to Familial Mediterranean fever.Biological therapies for the treatment of Behçet's disease-related uveitis beyond TNF-alpha blockade: a narrative review.Canakinumab Investigated for Treating Familial Mediterranean Fever.Treatment of colchicine-resistant Familial Mediterranean fever in children and adolescents.[Evidence of treatment of chronic inflammation in childhood and adolescence with biologics].[Update: Behçet's disease].The purinergic P2×7 receptor is expressed on monocytes in Behçet's disease and is modulated by TNF-α
P2860
Q26799747-1341D053-6BF6-44D7-9A18-65EC6800DC74Q26799767-8A6CF36D-85CE-4699-91B8-2D8899CC90DDQ33908217-1CF8D9EE-05C4-4513-A8FE-8CC5B922E145Q35086225-52978B54-3B82-4183-8AB7-482C47409B78Q35133812-B7CF73C0-27BC-4C52-B5D4-DEB447C6E216Q35219001-8FE05C09-12E1-4B2F-ADBC-8271204BE252Q35692083-5A042B8A-B998-4DF0-A70E-0BFC8DD39AC7Q36816872-C98EEC90-0021-4486-B6D4-F5332FC9E91FQ37077564-1928F207-6D51-41DB-8C23-5C6B2CDA5572Q37624811-A4A4ECE1-D76B-4E02-90A3-E10328573D7CQ37636664-F403712D-EBFA-4EB5-A653-3AD4A0C8DA72Q37716334-B8F45E8D-ED0D-4EB9-903A-C87E91B987D5Q37802305-4F4036AB-62AE-4226-8986-6E700EBBC9A8Q37848193-DD0FCC5F-EDF4-42C9-960E-461EB887D1ADQ37848210-258E2AF2-C613-4936-807E-A751FA3FE514Q37901519-9CF31A63-A7AA-4741-871D-F66C093B3990Q37979862-B6E43DB1-BC87-4302-AEF3-BDF5641DE282Q38004932-45811D5E-7590-4714-B189-ACE8E2AF80BCQ38074355-56C53434-8E36-4DDB-9AED-DF8886FDBDF3Q38097750-488EC804-6345-4F14-9D16-898C6E327A7CQ38122566-8660956D-3E6E-4ECF-9BF7-111F90A8FD21Q38151758-76A6F9B2-A84F-4B52-BA68-CE2AF8C5DA11Q38759360-929188DB-0B7A-4C66-B767-74FD6EE2E8CAQ38830790-975DCDAC-A5EA-4355-82CF-E8E78045D283Q39096171-CC314060-8241-4D72-B20C-F8BDB850A95DQ39426709-E0740C7D-C30E-444C-AEF2-9919132F53FCQ40045785-4B66A311-3631-4CD1-AB78-9312BEFF58F9Q40089782-6D44D658-BB13-4B23-8075-50555B53A490Q40154874-FEB3402B-728C-4C20-9B95-C497BD2D992DQ40179129-9CC893D5-EEAE-43D3-A79D-C54F9C5B7272Q48630386-2215B872-729B-4DA6-8451-136E275E37FAQ58326160-AD099792-8814-4ED1-A49D-46163706A9E0
P2860
Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet's disease.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Anti-IL-1 treatment for second ...... with FMF and Behçet's disease.
@en
type
label
Anti-IL-1 treatment for second ...... with FMF and Behçet's disease.
@en
prefLabel
Anti-IL-1 treatment for second ...... with FMF and Behçet's disease.
@en
P2093
P1476
Anti-IL-1 treatment for second ...... with FMF and Behçet's disease.
@en
P2093
Nuray Aktay Ayaz
Yelda Bilginer
P304
P356
10.1007/S10067-009-1279-8
P577
2009-09-23T00:00:00Z